Poire , X , Labopin , M , Polge , E , Passweg , J , Craddock , C , Blaise , D , Cornelissen , J J , Volin , L , Russell , N H , Socie , G , Michallet , M , Fegueux , N , Chevallier , P , Brecht , A , Hunault-Berger , M , Mohty , M , Esteve , J & Nagler , A 2018 , ' Allogeneic stem cell transplantation benefits for patients >= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation ' , Haematologica , vol. 103 , no. 2 , pp. 256-265 . https://doi.org/10.3324/haematol.2017.178251
Title: | Allogeneic stem cell transplantation benefits for patients >= 60 years with acute myeloid leukemia and FLT3 internal tandem duplication : a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation |
Author: | Poire, Xavier; Labopin, Myriam; Polge, Emmanuelle; Passweg, Jakob; Craddock, Charles; Blaise, Didier; Cornelissen, Jan J.; Volin, Liisa; Russell, Nigel H.; Socie, Gerard; Michallet, Mauricette; Fegueux, Nathalie; Chevallier, Patrice; Brecht, Arne; Hunault-Berger, Mathilde; Mohty, Mohamad; Esteve, Jordi; Nagler, Arnon |
Contributor organization: | Clinicum Department of Oncology Hematologian yksikkö HUS Comprehensive Cancer Center |
Date: | 2018-02 |
Language: | eng |
Number of pages: | 10 |
Belongs to series: | Haematologica |
ISSN: | 0390-6078 |
DOI: | https://doi.org/10.3324/haematol.2017.178251 |
URI: | http://hdl.handle.net/10138/233487 |
Abstract: | Intermediate-risk cytogenetic acute myeloid leukemia with an internal tandem duplication of FLT3 (FLT3-ITD) is associated with a high risk of relapse, and is now a standard indication for allogeneic stem cell transplantation. Nevertheless, most studies supporting this strategy have been performed in young patients. To address the benefit of allogeneic transplantation in the elderly, we made a selection from the European Society for Blood and Marrow Transplantation registry of de novo intermediate-risk cytogenetic acute myeloid leukemia harboring FLT3-ITD in patients aged 60 or over and transplanted from a related or unrelated donor between January 2000 and December 2015. Two hundred and ninety-one patients were identified. Most patients received a reduced-intensity conditioning (82%), while donors consisted of an unrelated donor in 161 (55%) patients. Two hundred and twelve patients received their transplantation in first remission, 37 in second remission and 42 in a more advanced stage of the disease. The 2-year leukemia-free survival rate was 56% in patients in first remission, 22% in those in second remission and 10% in patients with active disease, respectively (P= 60 with FLT3-ITD acute myeloid leukemia in first remission, similarly to current treatment recommendations for younger patients. |
Subject: |
CYTOGENETICALLY NORMAL AML
ACUTE MYELOGENOUS LEUKEMIA 1ST COMPLETE REMISSION GERIATRIC ASSESSMENT PROGNOSTIC IMPACT NPM1 MUTATIONS OLDER PATIENTS ALLELIC RATIO HEMATOLOGIC MALIGNANCIES SORAFENIB MAINTENANCE 3122 Cancers |
Peer reviewed: | Yes |
Rights: | cc_by_nc |
Usage restriction: | openAccess |
Self-archived version: | publishedVersion |
Total number of downloads: Loading...
Files | Size | Format | View |
---|---|---|---|
256.full.pdf | 438.7Kb |
View/ |